Addition of inflammation-related biomarkers to the CAIDE model for risk prediction of all-cause dementia, Alzheimer’s disease and vascular dementia in a prospective study

[1] Mahase E(2021)Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns BMJ 375 n3127-1718

[2] Alexander GC(2021)Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility JAMA 325 1717-849

[3] Emerson S(2023)Anti-amyloid antibody therapies in Alzheimer’s disease Brain 146 842-576

[4] Kesselheim AS(2023)Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics Drugs 83 569-379

[5] Perneczky R(2019)Models for predicting risk of dementia: a systematic review J Neurol Neurosurg Psychiatry 90 373-569

[6] Jessen F(2019)Statistical methods for dementia risk prediction and recommendations for future work: A systematic review Alzheimer's & Dementia: Translational Research & Clinical Interventions 5 563-326

[7] Grimmer T(2015)Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review PLoS ONE 10 e0136181-741

[8] Levin J(2010)Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol 6 318-570

[9] Flöel A(2006)Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study The Lancet Neurology 5 735-1059

[10] Peters O(2014)Midlife risk score for the prediction of dementia four decades later Alzheimers Dement 10 562-655

[1] Mahase E(2021)Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns BMJ 375 n3127-1718

[2] Alexander GC(2021)Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility JAMA 325 1717-849

[3] Emerson S(2023)Anti-amyloid antibody therapies in Alzheimer’s disease Brain 146 842-576

[4] Kesselheim AS(2023)Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics Drugs 83 569-379

[5] Perneczky R(2019)Models for predicting risk of dementia: a systematic review J Neurol Neurosurg Psychiatry 90 373-569

[6] Jessen F(2019)Statistical methods for dementia risk prediction and recommendations for future work: A systematic review Alzheimer's & Dementia: Translational Research & Clinical Interventions 5 563-326

[7] Grimmer T(2015)Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review PLoS ONE 10 e0136181-741

[8] Levin J(2010)Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol 6 318-570

[9] Flöel A(2006)Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study The Lancet Neurology 5 735-1059

[10] Peters O(2014)Midlife risk score for the prediction of dementia four decades later Alzheimers Dement 10 562-655